MedTrace Logo

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

NCT02197897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-01-13

Study results available
· View outcomes & findings →

Summary

Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors

Conditions

Interventions

DRUG

Tamoxifen Citrate

Single-center, two-stage phase-II clinical trial (Simon design)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Guilherme Godoy, M.D. · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2017-09-12
Completion
2019-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197897 on ClinicalTrials.gov